Manidipine-d4 (Synonyms: Franidipine-d4, (±)-Manidipine-d4) |
Catalog No.GC47597
One-Click Copy Product Info
|
An internal standard for the quantification of manidipine
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1189656-59-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Manidipine-d4 is intended for use as an internal standard for the quantification of manidipine by GC- or LC-MS. Manidipine is a dihydropyridine L- and T-type calcium channel blocker.1,2,3 It inhibits recombinant rabbit L-type (α1Cα2/δβ1a) and human T-type (α1H) calcium channels expressed in Xenopus oocytes and native L-type channels in dissociated guinea pig cardiac ventricular cells (IC50 = 2.6 nM). Manidipine inhibits intracellular calcium increases induced by endothelin-1 in A7r5 rat vascular smooth muscle cells (ED50 = 1 nM) and potassium-induced contraction of isolated dog femoral and portal veins (IC50s = 24 and 2.1 nM, respectively).4,5 In vivo, it lowers blood pressure in spontaneously hypertensive rats (SHRs) when administered at a dose of 10 mg/kg and inhibits left ventricular hypertrophy in rats induced by isoproterenol when administered at a dose of 3 mg/kg.6,7 Formulations containing manidipine have been used in the treatment of hypertension.
1.Furukawa, T., Nukada, T., Miura, R., et al.Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (α1G) expressed in Xenopus oocytesJ. Cardiovasc. Pharmacol.45(3)241-246(2005) 2.Furukawa, T., Nukada, T., Namiki, Y., et al.Five different profiles of dihydropyridines in blocking T-type Ca2+ channel subtypes (Cav3.1 (α1G), Cav3.2 (α1H), and Cav3.3 (α1I)) expressed in Xenopus oocytesEur. J. Pharmacol.613(1-3)100-107(2009) 3.Tohse, N., Takeda, Y., and Kanno, M.Voltage-dependent modulation of L-type Ca2+ current by manidipine in guinea-pig heart cellsEur. J. Pharmacol.249(2)231-233(1993) 4.Huang, S., Simonson, M.S., and Dunn, M.J.Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cellsAm. Heart J.125(2 Pt 2)589-597(1993) 5.Shibouta, Y., Kitayoshi, T., Kitoh, G., et al.Calcium channel blocking action of franidipine hydrochloride (CV-4093.2HCl) in vitro and in vivoJpn. J. Pharmacol.48(4)463-472(1988) 6.Meguro, K., Aizawa, M., Sohda, T., et al.New 1,4-dihydropyridine derivatives with potent and long-lasting hypotensive effectChem. Pharm. Bull. (Tokyo)33(9)3787-3797(1985) 7.Yoshiyama, M., Takeuchi, K., Kim, S., et al.Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophyJpn. Circ. J.62(1)47-52(1998)
| Cas No. | 1189656-59-4 | SDF | |
| Synonymes | Franidipine-d4, (±)-Manidipine-d4 | ||
| Canonical SMILES | O=C(OC)C1=C(C)NC(C)=C(C(OC([2H])([2H])C([2H])([2H])N2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)=O)C1C5=CC([N+]([O-])=O)=CC=C5 | ||
| Formula | C35H34D4N4O6 | M.Wt | 614.7 |
| Solubility | Methanol: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6268 mL | 8.134 mL | 16.2681 mL |
| 5 mM | 325.4 μL | 1.6268 mL | 3.2536 mL |
| 10 mM | 162.7 μL | 813.4 μL | 1.6268 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)